The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2020 | Future directions of CLL cell proliferation research
Jan Burger, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the future areas of research that need to be explored in chronic lymphocytic leukemia (CLL) such as why some cells are resistant to treatment. By better understanding what other signaling pathways might be involved in CLL cell proliferation, resistance to current treatments can be prevented and the development of new treatments can take place. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
